SCHEMBL213625

SCHEMBL213625

NC(CS)C(=O)NCC(=O)O

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGS1 P23219 2/20 0.53
GSTK1 Q9Y2Q3 1/20 0.53
ALDH1A1 P00352 3/20 0.52
MAPT P10636 2/20 0.52
LMNA P02545 1/20 0.52
PTGS2 P35354 1/20 0.52
TDP1 Q9NUW8 1/20 0.52
SLC7A11 Q9UPY5 1/20 0.50
MMP2 P08253 1/20 0.47
MME P08473 5/20 0.46
ACE P12821 3/20 0.46
ECE1 P42892 2/20 0.46
HPGD P15428 1/20 0.46
MAPK1 P28482 1/20 0.46
HSD17B10 Q99714 1/20 0.46
MEN1 O00255 1/20 0.46
BLM P54132 1/20 0.46
NPEPPS P55786 1/20 0.46
KMT2A Q03164 1/20 0.46
CPA1 P15085 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL213626 1.00 PTGS1 (0.53) PTGS1GSTK1ALDH1A1MAPTLMNA
SCHEMBL27574429 1.00 PTGS1 (0.53) PTGS1GSTK1ALDH1A1MAPTLMNA
SCHEMBL11766266 1.00 PTGS1 (0.53) PTGS1GSTK1ALDH1A1MAPTLMNA
SCHEMBL27922239 0.98 PTGS1 (0.51) PTGS1GSTK1ALDH1A1MAPTLMNA
SCHEMBL27922237 0.98 PTGS1 (0.51) PTGS1GSTK1ALDH1A1MAPTLMNA
SCHEMBL3393046 0.94 ALDH1A1 (0.52) PTGS1GSTK1ALDH1A1MAPTLMNA
SCHEMBL3393040 0.94 ALDH1A1 (0.52) PTGS1GSTK1ALDH1A1MAPTLMNA
Cysteine SCHEMBL6014792 0.94 PTGS1 (0.61) PTGS1GSTK1ALDH1A1MAPTLMNA
Cysteine SCHEMBL6014796 0.94 PTGS1 (0.61) PTGS1GSTK1ALDH1A1MAPTLMNA
Glycine SCHEMBL28155782 0.94 PTGS1 (0.49) PTGS1GSTK1ALDH1A1MAPTLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1742 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12595229-B2 Method for producing derivative of organic substance and method for analyzing sample containing organic substance AJINOMOTO CO., INC. (JP) 2026-04-07 US claimed
US-12584924-B2 Compositions and methods for diagnosing and treating chronic kidney disease SOCIETE DES PRODUITS NESTLE S.A. (CH) 2026-03-24 US claimed
US-20250336540-A1 METABOLITE PREDICTORS FOR LUNG CANCER JANSSEN PHARMACEUTICA NV (BE) 2025-10-30 US claimed
US-20250334558-A1 TOTAL HYDROGEN SULFIDE QUANTIFICATION CLEVELAND CLINIC FOUND (US) 2025-10-30 US claimed
US-20250269072-A1 PROCESSES FOR PREPARING RADIOLABELLED CONJUGATES CENTENARY INST OF CANCER MEDICINE AND CELL BIOLOGY (AU) 2025-08-28 US claimed
EP-4598347-A1 KITS AND USE THEREOF IN SURGICAL PROCEDURES FOR ENDOSCOPIC HARVESTING OF VESSELS Marizyme, Inc. (US) 2025-08-13 EP claimed
EP-4577190-A1 ANTIOXIDANT-CONTAINING EYE DROP FORMULATIONS AND METHODS OF PREVENTION AND/OR TREATMENT USING SAME Marizyme, Inc. (US) 2025-07-02 EP claimed
US-12344871-B2 Method for producing cysteine from glutathione AMANO ENZYME INC. (JP) 2025-07-01 US claimed
US-20250152494-A1 COSMETIC COMPOSITION CONTAINING RETINOID, EXTRACT OF CENTELLA ASIATICA AND A DIPEPTIDE THE BOOTS COMPANY PLC (GB) 2025-05-15 US claimed
CN-119969563-A Method for preparing flavoring agent 联合利华知识产权控股有限公司 2025-05-13 CN claimed
EP-0777472-A2 METHODS FOR IDENTIFYING AND TREATING RESISTANT TUMORS ELI LILLY AND COMPANY (US) 1997-06-11 EP claimed
EP-0675712-A4 REDUCTION OF HAIR GROWTH EMPLOYING SULFHYDRYL REACTIVE COMPOUNDS. HANDELMAN JOSEPH H (US) 1996-11-06 EP claimed
WO-1996006604-A2 METHODS FOR IDENTIFYING AND TREATING RESISTANT TUMORS ELI LILLY AND COMPANY (US) 1996-03-07 WO claimed
EP-0675712-A1 REDUCTION OF HAIR GROWTH EMPLOYING SULFHYDRYL REACTIVE COMPOUNDS HANDELMAN, Joseph H. (US) 1995-10-11 EP claimed
US-5411991-A Applying to human skin, beards, reaction with cysteine GILLETTE COMPANY, THE, A DELAWARE CORPORATION 1995-05-02 US claimed
EP-0604433-A4 COMPOSITION AND METHOD FOR DISEASE TREATMENT. LIFE SCIENCES TECH INC (US) 1994-10-12 EP claimed
WO-1994014428-A1 REDUCTION OF HAIR GROWTH EMPLOYING SULFHYDRYL REACTIVE COMPOUNDS HANDELMAN, JOSEPH, H. (US) 1994-07-07 WO claimed
EP-0604433-A1 COMPOSITION AND METHOD FOR DISEASE TREATMENT LIFE SCIENCES' TECHNOLOGIES, INC. (US) 1994-07-06 EP claimed
WO-1992021368-A1 COMPOSITION AND METHOD FOR DISEASE TREATMENT LIFE SCIENCES' TECHNOLOGIES, INC. (US) 1992-12-10 WO claimed
WO-1990003666-A1 STATE OF CHARGE OF REDOX CELL UNISEARCH LIMITED (AU) 1990-04-05 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250269072-A1 PROCESSES FOR PREPARING RADIOLABELLED CONJUGATES AS3MT, TP53, ANXA5 PTGS1 4705/4885GSTK1 385/4885ALDH1A1 2153/4885
US-12595229-B2 Method for producing derivative of organic substance and method for analyzing sample containing organic substance SULT1E1, CNR2, SRMS PTGS1 759/4885GSTK1 1530/4885ALDH1A1 672/4885
US-20250152494-A1 COSMETIC COMPOSITION CONTAINING RETINOID, EXTRACT OF CENTELLA ASIATICA AND A DIPEPTIDE RARA, RARG, RARB PTGS1 4533/4885GSTK1 1472/4885ALDH1A1 1732/4885
US-12584924-B2 Compositions and methods for diagnosing and treating chronic kidney disease GLS, AADAT, FGF23 PTGS1 2333/4885GSTK1 3525/4885ALDH1A1 822/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.